New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
11:32 EDTNSR, PWRD, QIWI, AZN, SHLD, DB, ARUN, WUBA, KERX, SPRDOptions with decreasing implied volatility:
Options with decreasing implied volatility: NSR KERX WUBA ARUN DB SHLD AZN QIWI PWRD SPLS
News For NSR;KERX;WUBA;ARUN;DB;SHLD;AZN;QIWI;PWRD;SPRD From The Last 14 Days
Check below for free stories on NSR;KERX;WUBA;ARUN;DB;SHLD;AZN;QIWI;PWRD;SPRD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
August 21, 2014
09:50 EDTSHLDSears falls after earnings, levels to watch
The stock is down 4.7% to $34.24 at time of writing following a much wider than expected loss for the company's Q2. At current price support is at the session low at $33.51 and then at $32.62. Resistance is at $35.16.
09:44 EDTWUBA58.com falls after results, outlook
Shares gapped down at the open to $46.15 and have bounced slightly following earnings and outlook from the company before the bell. At the current price of $46.72, support is at $46.15 and the low of the day at $45.30. Resistance is at $47.24, the session high so far, and then at $48.59.
09:37 EDTSHLDActive equity options trading on open
Subscribe for More Information
09:07 EDTWUBA, SHLDOn The Fly: Pre-market Movers
Subscribe for More Information
07:47 EDTAZNPfizer looking at new targets, including Actavis, Bloomberg reports
While it weighs another attempt to acquire AstraZeneca (AZN), Pfizer is considering other overseas alternatives, including Actavis (ACT), Bloomberg reports, citing people familiar with the matter. Pfizer prefers to reach a deal with AstraZeneca, and a move on another company is unlikely "anytime soon," Bloomberg adds, citing its sources. Shares of Actavis are rising 3%, or $6.65, to $230.01 in pre-market trading, while AstraZeneca is up 2% to $72.59. Reference Link
06:04 EDTSHLDSears reports Q2 EPS ($5.39), consensus ($2.63)
Subscribe for More Information
05:42 EDTAZNIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 20, 2014
20:05 EDTWUBA58.com sees Q3 revenues $66M-$68M, consensus $72.60M
20:04 EDTWUBA58.com reports Q2 adjusted EPS 15c, consensus 8c
Subscribe for More Information
15:26 EDTWUBANotable companies reporting before tomorrow's open
Subscribe for More Information
15:17 EDTSHLDSears Holdings August weekly 36.5 straddle priced for 8.5% move into Q2
Subscribe for More Information
August 19, 2014
09:07 EDTPWRDOn The Fly: Pre-market Movers
Subscribe for More Information
07:54 EDTSHLDSears Holdings August weekly volatility increases into Q2 and outlook
Sears Holdings August weekly call option implied volatility is at 126, September is at 55, December is at 46, March is at 46; compared to its 26-week average of 55 according to Track Data, suggesting large near term price movement into the expected release of Q2 results on August 21.
07:01 EDTAZNDOJ closes investigation into PLATO Brilinta clinical trial, plans no action
AstraZeneca today announced that it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial with BRILINTA tablets. The government is not planning any further action. Pascal Soriot, CEO, said: “We welcome the Department of Justice’s decision not to pursue further action. We have always had absolute confidence in the integrity of the PLATO trial and we are proud of the important benefit BRILINTA offers to patients around the world suffering from acute coronary syndrome. As one of AstraZeneca’s growth platforms, we remain committed to delivering the full potential of this important medicine.” As part of our continued commitment to advancing the science behind cardiovascular medicine, AstraZeneca has initiated a clinical trial program for BRILINTA, its largest program involving more than 80,000 patients worldwide.
August 18, 2014
17:03 EDTPWRDPerfect World sees Q3 revenue RMB 956M-RMB 1B
Subscribe for More Information
17:02 EDTPWRDPerfect World reports Q2 EPS 55c, consensus 41c
Subscribe for More Information
14:06 EDTPWRDPerfect World upgraded to Overweight from Equal Weight at Morgan Stanley
Subscribe for More Information
09:20 EDTDBDeutsche Bank appoints Shannon Americas Chief Information Officer
Subscribe for More Information
07:57 EDTAZNCambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.
August 15, 2014
06:51 EDTDBDeutsche Bank settles $810M RMBS case with BayernLB, Reuters says
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use